What is the recommended dosage of cefdinir (Omnicef) for children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cefdinir Dosing for Pediatric Patients

For children aged 6 months through 12 years, cefdinir should be dosed at 7 mg/kg every 12 hours OR 14 mg/kg once daily (maximum 600 mg/day), with the once-daily regimen appropriate for acute otitis media, sinusitis, and pharyngitis/tonsillitis, while twice-daily dosing is required for skin infections. 1

Standard Dosing Regimens

The FDA-approved dosing for pediatric patients provides two equivalent options 1:

  • Twice-daily dosing: 7 mg/kg every 12 hours
  • Once-daily dosing: 14 mg/kg every 24 hours (total daily dose remains 14 mg/kg for both regimens)
  • Maximum daily dose: 600 mg regardless of weight 1

Indication-Specific Considerations

Once-daily dosing (14 mg/kg/day) is effective for 1:

  • Acute bacterial otitis media (10 days duration)
  • Acute maxillary sinusitis (10 days duration)
  • Pharyngitis/tonsillitis (5-10 days duration)

Twice-daily dosing (7 mg/kg every 12 hours) must be used for 1:

  • Uncomplicated skin and skin structure infections (10 days duration)
  • Once-daily dosing has not been studied for skin infections 1

Weight-Based Practical Dosing

For common pediatric weights using the 250 mg/5 mL suspension 1:

  • 9 kg (20 lbs): Use 125 mg/5 mL product
  • 18 kg (40 lbs): 2.5 mL every 12 hours OR 5 mL once daily
  • 27 kg (60 lbs): 3.75 mL every 12 hours OR 7.5 mL once daily
  • 36 kg (80 lbs): 5 mL every 12 hours OR 10 mL once daily
  • ≥43 kg (95 lbs): 6 mL every 12 hours OR 12 mL once daily (maximum dose reached) 1

Clinical Context and Positioning

Cefdinir serves as an alternative agent, not first-line therapy, for most pediatric infections. The Infectious Diseases Society of America and Pediatric Infectious Diseases Society position cefdinir alongside cefixime, cefpodoxime, and ceftibuten as alternatives when treating β-lactamase-producing Haemophilus influenzae in community-acquired pneumonia, specifically when amoxicillin-clavulanate cannot be used 2, 3.

Important Limitation

High-dose amoxicillin (90 mg/kg/day) remains superior for resistant pneumococcal infections 3. Research demonstrates that even a higher cefdinir dose of 25 mg/kg once daily achieves pharmacodynamic effectiveness of <40% of the dosing interval against penicillin-nonsusceptible Streptococcus pneumoniae, indicating inadequate coverage for these resistant strains 4. This pharmacokinetic limitation reinforces cefdinir's role as an alternative rather than first-line agent for pneumococcal infections.

Special Populations

For pediatric patients with renal insufficiency (creatinine clearance <30 mL/min/1.73 m²), reduce the dose to 7 mg/kg (up to 300 mg) once daily 1.

For patients on hemodialysis, administer 7 mg/kg every other day, with an additional dose of 7 mg/kg given at the conclusion of each hemodialysis session 1.

Administration and Storage

  • May be administered without regard to meals 1
  • After reconstitution, suspension remains stable for 10 days at room temperature (25°C/77°F) 1
  • Shake well before each administration 1

Safety Profile

Cefdinir demonstrates good tolerability in pediatric populations 5. The most common adverse effect is diarrhea, occurring in approximately 12.5% of patients at standard doses 6, with rates increasing to 20% at higher doses (25 mg/kg) 4. The oral suspension has shown superior palatability compared to other oral antimicrobials, which may improve adherence 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cefdinir Dosing Guidelines for Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Clinical evaluation of cefdinir 10% granules in children].

The Japanese journal of antibiotics, 1991

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.